Publication / Source: Bioanalysis 4(13)
Authors: Ryan De Vooght-Johnson, Future Science Group
David A Cowan is Director of the London 2012 anti-doping laboratory as well as Director of the King’s College London Drug Control Centre, the UK’s only WADA-accredited anti-doping laboratory, and Head of the Department of Forensic Science and Drug Monitoring. Cowan co-founded the Drug Control Centre in 1978 and became its Director in 1990. He has published extensively in the field of pharmaceutical analysis, especially as it relates to detecting drug administration in sport, and was awarded a personal chair in pharmaceutical toxicology in 1996. Cowan became Head of the Department of Forensic Science and Drug Monitoring at King’s College London in 2002. He has served on a number of national and international committees, including the Council of Europe Working Party Investigating Drug Abuse in Sport that led to the first World Anti-Doping Convention, the Laboratory Representative on the International Olympic Committee’s Medical Commission, and WADA’s Laboratory Accreditation Subcommittee. He is a member of the Crippen Club for Distinguished Toxicologists. In 1998 he was awarded the IOC Trophy for Sport Ethics by the BOA. He was a founding member of the World Association of Anti-Doping Scientists and became its first President serving on its Executive Board between 2001 and 2004. He was a Visiting Laboratory Director at the Salt Lake City Winter Olympic Games 2002, where the first novel erythropoiesis-stimulating protein (NESP) positive was discovered. He was also a senior advisory scientist at both the Turin Winter Olympic Games in 2006 and the Beijing Olympic Games in 2008. He was also a member of the IOC Medical Commission for the Sydney Olympic Games in 2000 and the Vancouver Winter Olympic Games in 2010. The Drug Control Centre undertook the sample analysis during the 2002 Manchester Commonwealth Games and Cowan was Co-Director of the laboratory for the Commonwealth Games in Kuala Lumpur in 1998. Cowan, who has directed the laboratory at King’s College London for many years, was a member of the bid team making the presentation to the International Olympic Committee in February 2005.
Campbell P Barker has been leading GlaxoSmithKline’s delivery of the London 2012 laboratory services since September 2009. Prior to that time he was Director of Global Strategic Projects in GlaxoSmithKline’s Consumer Healthcare business from 2006, and from 1994 to 2006 he worked in R&D for Procter & Gamble. Barker holds a PhD in chemistry from the University of Durham.